.
TORONTO (ON) / ACCESSWIRE/January 12, 2023 StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) (“StageZeroOr the “Company“, a vertically integrated health company that aims to improve the detection and management for cancer and other chronic conditions through molecular diagnostics and clinical intervention.ExchangeTo extend the expiry of 6,492,420 common sharepurchase warrants (the “Warrants“” expires the 16th or 31st January 2023 to the 31st January 2024.
Original Warrants were issued under non-brokered private placements or debenture converts. No Warrants are directly or indirectly held by Company insiders.
Below is a table that lists the prices for exercising Warrants.
| The Issue Date | Exercise Price | The current expiry date | There are many warrants |
| 25-Mar-2019 | 0.72 | 31-Jan-2023 | 722,606 |
| 23-Apr-2019 | 0.8 | 31-Jan-2023 | 390,626 |
| 23-Apr-2019 | 0.96 | 31-Jan-2023 | 220,797 |
| 23-Apr-2019 | 1.528 | 31-Jan-2023 | 319,095 |
| 10-Jul-2019 | 1.48 | 31-Jan-2023 | 1,448,597 |
| 24-Jul-2019 | 1.48 | 31-Jan-2023 | 566,875 |
| 19-Feb-2020 | 0.56 | 31-Jan-2023 | 202,344 |
| 08-Jul-2020 | 0.56 | 31-Jan-2023 | 31,250 |
| 09-Jul-2020 | 0.56 | 31-Jan-2023 | 78,125 |
| 28-Sep-2020 | 0.56 | 31-Jan-2023 | 50,782 |
| 29-Sep-2020 | 0.56 | 31-Jan-2023 | 54,688 |
| 27-Oct-2020 | 0.56 | 31-Jan-2023 | 15,625 |
| 25-Jan-2021 | 0.56 | 31-Jan-2023 | 62,500 |
| 28-Jan-2021 | 0.56 | 31-Jan-2023 | 273,438 |
| 29-Jan-2021 | 0.56 | 31-Jan-2023 | 490,625 |
| 29-Jan-2021 | 0.56 | 31-Jan-2023 | 343,750 |
| 25-Feb-2021 | 0.56 | 31-Jan-2023 | 23,438 |
| 01-Mar-2021 | 0.56 | 31-Jan-2023 | 9,375 |
| 09-Mar-2021 | 0.56 | 31-Jan-2023 | 234,375 |
| 25-Mar-2021 | 0.56 | 31-Jan-2023 | 31,250 |
| 18-Aug-2021 | 0.56 | 31-Jan-2023 | 62,500 |
| 19-Aug-2021 | 0.56 | 31-Jan-2023 | 69,653 |
| 16-Jan-2020 | 0.48 | 16-Jan-2023 | 790,106 |
Amendments to Warrants are effective January 30, 2023. This date is subject to approval by the Toronto Stock Exchange.
We have responded to shareholders that participated in previous financings and applied to the TSX for a prolongation of the warrants issued during those financings up to January 31, 2024. “This is our support for all those who participated in our financings. It also serves as an ongoing source of capital that could fund our continued growth. This amount can be up to C$6.03million if all warrants are exercised,” stated James Howard-Tripp Chairman and CEO StageZero. We thank all shareholders for their continued support.
StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd., a vertically integrated health company, aims to improve the detection and management early of chronic diseases such as cancer. It offers next-generation diagnostics, a unique program for telehealth, and clinical interventions that help patients lower their risk of late-stage illness (AVRT(tm).
Aristotle(r) is the Company’s next-generation test. It screens for multiple types of cancer using a single blood sample. This panel has high specificity and sensitivity. Aristotle(r), which uses mRNA technology for identifying the molecular signatures multiple types of cancer, is built upon the Company’s patent technology platform, The Sentinel Principle. The technology’s underlying principle has been used in North America by over 100,000 patients. It was validated in over 9,000 patients.
Aristotle (r), along with additional cancer diagnostics (ColonSentry, BreastSentry, and the Prostate Health Index), are processed by the Company’s clinical lab, StageZero Life Sciences, Inc., a CAP-accredited and CLIA accredited high-complexity laboratory located in Richmond, Virginia. The Company also leverages its expertise in polymerase chain reactions (PCR) testing for COVID-19 testing (swab, saliva and blood analysis) as well as Antibody Testing (blood test).
StageZero Life Sciences trades under the symbol SZLSF on the Toronto Stock Exchange and the OTCQB.
Forward-looking statements
Forward-looking statements are identified with words like “expects,” “will”, and other similar expressions in this press release. These words reflect current company expectations about future events. Forward-looking statements are subject to risks and uncertainties. Actual events could differ from what is projected. For more information about the risks and uncertainties associated with these forward-looking statements, investors should refer to the Company’s quarterly filings as well as its annual reports. These forward-looking statements should not be relied upon by the reader. Except as required by law, the Company is not obligated to revise these forward-looking statements.
Contact:
Relations with Investors
Rebecca Greco
1-855-420-7140 ext. 1838
[email protected]
SOURCE: StageZero Life Sciences Ltd